President Donald Trump just announced deals with drugmakers Eli Lilly and Novo Nordisk that will yield lower prices for GLP-1 ...
U.S. regulators launch new review of infant RSV therapies from Merck, Sanofi, and AstraZeneca amid scrutiny by Health Secretary Robert F. Kennedy Jr.
Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems ...
Federal officials say the U.S. Food and Drug Administration (FDA) is reviewing reports of possible deaths in adults and ...
Key Takeaways The U.S. Food and Drug Administration is reviewing two RSV drugs for infantsNo safety issues have been ...
MedPage Today on MSN
ADC post-endocrine therapy misses mark in advanced breast cancer trial
SAN ANTONIO -- The antibody-drug conjugate (ADC) sacituzumab govitecan (Trodelvy) failed to outperform chemotherapy as first ...
The addition of tucatinib to first-line trastuzumab plus pertuzumab delayed disease progression among a cohort of women with ...
AstraZeneca PLC (NASDAQ:AZN) is one of the best pharma stocks to invest in. AstraZeneca PLC (NASDAQ:AZN) received a rating ...
The agency also is reviewing safety of immunizations for RSV, according to manufacturers of the therapies who have been ...
Federal health officials confirm a sweeping investigation into potential adult deaths linked to coronavirus immunizations.
Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they were treated with sacituzumab govitecan-hziy (Trodelvy) or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback